Elevance Health, Inc. (ELV) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Elevance Health’s revenue went from $84.9B in fiscal 2016 to $199.1B in fiscal 2025, growth of about 9.9% a year.
Net income in fiscal 2025 was $5.7B, a net margin of 2.8%; the best year in this period was 2021 with $6.2B.
Over the twelve months to September 30, 2026, revenue was $201.8B and net income $5.1B.
Free cash flow was $3.2B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 16% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $201.8B | $199.1B | $177.0B | $171.3B | $156.6B | $138.6B | $121.9B | $104.2B | $92.1B | $90.0B | $84.9B |
| Gross profit | $179.7B | $177.9B | $157.3B | $154.0B | $143.6B | $127.7B | $112.9B | $102.2B | $92.1B | $90.0B | — |
| Operating income | $5.4B | $7.2B | $7.9B | $8.5B | $8.3B | $7.6B | $6.4B | $6.0B | $5.4B | $4.2B | $4.8B |
| Net income | $5.1B | $5.7B | $6.0B | $6.0B | $5.9B | $6.2B | $4.6B | $4.8B | $3.8B | $3.8B | $2.5B |
| EPS (diluted) | $23.52 | $25.21 | $25.68 | $25.22 | $24.28 | $24.95 | $17.98 | $18.47 | $14.19 | $14.35 | $9.21 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +12.5% | +3.3% | +9.4% | +13.0% | +13.8% | +16.9% | +13.2% | +2.3% | +6.1% | +7.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.6B | $4.3B | $5.8B | $8.1B | $8.4B | $8.4B | $10.7B | $6.1B | $3.8B | $4.2B | $3.3B |
| Capital spending | -$1.1B | -$1.1B | -$1.3B | -$1.3B | -$1.2B | -$1.1B | -$1.0B | -$1.1B | -$1.2B | -$791M | -$584M |
| Free cash flow | $6.5B | $3.2B | $4.6B | $6.8B | $7.2B | $7.3B | $9.7B | $5.0B | $2.6B | $3.4B | $2.7B |
| Dividends paid | $1.5B | $1.5B | $1.5B | $1.4B | $1.2B | $1.1B | $954M | $818M | $776M | $705M | $684M |
| Buybacks | $2.2B | $2.6B | $2.9B | $2.7B | $2.3B | $1.9B | $2.7B | $1.7B | $1.7B | $2.0B | $0 |
| Stock-based pay | $240M | $276M | $191M | $289M | $264M | $255M | $283M | $294M | $226M | $170M | $165M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $35.4B | $33.5B | $36.1B | $33.3B | $31.1B | $29.2B | $24.6B | $20.6B | $21.0B | $21.2B |
| Debt | — | $32.6B | $31.7B | $25.7B | $24.8B | $23.8B | $21.0B | $19.4B | $18.1B | $18.7B | $15.3B |
| Equity | — | $43.9B | $41.3B | $39.3B | $36.2B | $36.1B | $33.2B | $31.7B | $28.5B | $26.5B | $25.1B |
| Total assets | — | $121.5B | $116.9B | $108.9B | $102.8B | $97.5B | $86.6B | $77.5B | $71.6B | $70.5B | $65.1B |
| Shares (diluted) | 218M | 225M | 233M | 237M | 243M | 247M | 254M | 260M | 264M | 268M | 268M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 89.0% | 89.4% | 88.8% | 89.9% | 91.7% | 92.1% | 92.7% | 98.1% | 100.0% | 100.0% | — |
| Operating margin | 2.7% | 3.6% | 4.4% | 5.0% | 5.3% | 5.5% | 5.2% | 5.8% | 5.9% | 4.6% | 5.7% |
| Net margin | 2.5% | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | 3.8% | 4.6% | 4.1% | 4.3% | 2.9% |
| FCF margin | 3.2% | 1.6% | 2.6% | 4.0% | 4.6% | 5.2% | 7.9% | 4.8% | 2.8% | 3.8% | 3.2% |
| ROIC | — | 8.0% | 8.1% | 10.2% | 10.5% | 9.7% | 8.6% | 9.4% | 8.6% | 9.0% | 6.5% |
| ROE | — | 12.9% | 14.5% | 15.2% | 16.3% | 17.1% | 13.8% | 15.2% | 13.1% | 14.5% | 9.8% |
Frequently asked questions
What is Elevance Health’s annual revenue?
$199.1B in fiscal 2025 and $201.8B over the twelve months to September 30, 2026.
How much profit does Elevance Health make?
Net income was $5.7B in fiscal 2025 (net margin 2.8%).
Is Elevance Health’s revenue growing?
Yes: revenue rose 12.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.